MINNEAPOLIS , March 21, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced the peer-reviewed publication of an analysis of available ultrafiltration clinical trials with findings that

MINNEAPOLIS , March 01, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), today announced that, effective February 23, 2023 , the Company’s independent directors approved equity awards under Nuwellis’ 2021 Inducement Plan, as material inducements to six individuals entering into employment

Q4 Revenue Up 42%; Expansion of Clinical Evidence Sets Stage for 2023 Growth MINNEAPOLIS , Feb. 28, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today reported financial results for the fourth

MINNEAPOLIS , Feb. 23, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced that Nestor Jaramillo , President and Chief Executive Officer, and Lynn Blake , Chief Financial Officer, will

New guidelines from cardiothoracic surgical societies emphasize the importance of volume maintenance during cardiac procedures MINNEAPOLIS , Feb. 23, 2023 (GLOBE NEWSWIRE) -- A recent editorial published in The Annals of Thoracic Surgery provides additional clinical evidence to support the role

MINNEAPOLIS , Feb. 07, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, announced today that its fourth quarter and full year 2022 financial results will be released on Tuesday, February 28, 2023 .

MINNEAPOLIS , Jan. 09, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a medical technology company focused on transforming the lives of people with fluid overload, today announced preliminary unaudited results for fourth quarter and full year 2022.

Dr. Jefferies brings over two decades of cardiology and heart failure expertise to Nuwellis as the Company expands clinical evidence supporting the use of ultrafiltration for people with fluid overload MINNEAPOLIS , Jan. 05, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc.

MINNEAPOLIS , Jan. 04, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced that the Company held its adjourned special meeting of stockholders on January 4, 2023 at 2:00 p.m.